Top Page
Aiml Resources
(AIML)
Aiml Resources (AIML) vs. iShares MSCI Canada ETF (EWC)
Aiml Resources Business Overview & Revenue Model
Aiml Resources Financial Statement Overview
| Breakdown | TTM | Jul 2025 | Jul 2024 | Apr 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 168.26K | 167.31K | 600.14K | 487.50K | 65.41K | 0.00 |
| Gross Profit | -419.91K | 162.81K | 294.86K | 466.01K | 65.41K | 0.00 |
| EBITDA | -5.97M | -4.85M | -1.67M | -1.36M | -3.42M | -1.43M |
| Net Income | -6.58M | -4.59M | -3.29M | -1.42M | -3.17M | -2.73M |
Balance Sheet | ||||||
| Total Assets | 2.54M | 3.41M | 329.69K | 1.51M | 2.04M | 3.59M |
| Cash, Cash Equivalents and Short-Term Investments | 1.13M | 2.00M | 216.86K | 14.56K | 525.24K | 3.49M |
| Total Debt | 183.35K | 198.19K | 197.72K | 859.98K | 261.34K | 320.29K |
| Total Liabilities | 952.26K | 855.77K | 1.54M | 1.79M | 1.55M | 1.51M |
| Stockholders Equity | 1.62M | 2.60M | -1.17M | -247.46K | 1.08M | 2.31M |
Cash Flow | ||||||
| Free Cash Flow | -5.59M | -3.99M | -1.64M | -634.28K | -3.02M | -959.00K |
| Operating Cash Flow | -5.59M | -3.99M | -1.64M | -634.28K | -3.02M | -931.35K |
| Investing Cash Flow | -3.72K | -1.15K | -325.98K | -210.64K | -1.14M | -11.38K |
| Financing Cash Flow | 5.56M | 5.78M | 2.16M | 374.37K | 1.27M | 4.17M |
Aiml Resources Technical Analysis
Aiml Resources Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | C$9.33M | -11.57 | ― | ― | 16.04% | -455.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | C$31.91M | -9.48 | 3086.87% | ― | -48.53% | -9.66% | |
45 Neutral | C$10.36M | -5.12 | 6239.15% | ― | ― | 48.94% | |
43 Neutral | C$8.89M | -2.06 | -1143.80% | ― | -64.23% | 18.42% | |
42 Neutral | C$6.25M | -4.68 | ― | ― | ― | 81.01% | |
33 Underperform | C$11.43M | -21.40 | 527.45% | ― | ― | -67.11% |
Aiml Resources Corporate Events
AI/ML Innovations Inc., a global digital health technology company leveraging AI and neural networks to transform biometric data into clinical insights, is listed on the Canadian Securities Exchange, the OTCQB Venture Market and the Frankfurt Stock Exchange. The firm’s platforms target earlier diagnosis, personalized treatments and improved care outcomes in the healthcare sector.
The company has announced a proposed non-brokered private placement of up to $3 million in convertible debentures, carrying 10% annual interest and maturing in three years, which are convertible into units at $0.05 per unit, each unit including a common share and a warrant exercisable at $0.15 for 36 months. The financing, which remains subject to Canadian Securities Exchange approval, is intended to bolster AIML’s capital structure and could meaningfully expand its equity base if fully converted, with implications for both funding capacity and shareholder dilution.
The most recent analyst rating on (TSE:AIML) stock is a Sell with a C$0.03 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
AI/ML Innovations’ subsidiary Neural Cloud Solutions has signed a distribution agreement with Chile-based digital health provider Intelimed.ai to commercialize its MaxYield, CardioYield and Insight 360 cardiac software platforms across Latin America. Intelimed is granted exclusive distribution rights in Chile and non-exclusive rights in the wider region, targeting hospitals, clinics, diagnostic providers, OEMs, telemedicine firms and research institutions.
The deal positions Chile as a strategic anchor market and taps Intelimed’s existing network and “platform” model for clinical AI, aiming to accelerate adoption of Neural Cloud’s ECG enhancement and automated reporting tools. With Latin America seeking scalable, cost-effective diagnostic technologies, the partnership is intended to expand access to advanced cardiac AI solutions that fit local clinical workflows while adhering to international standards, potentially strengthening AIML’s regional foothold in digital health.
The most recent analyst rating on (TSE:AIML) stock is a Sell with a C$0.04 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
NeuralCloud Solutions, a subsidiary of AI/ML Innovations, has entered a non-binding agreement with Finnish wearable sensor specialist Movesense to pilot AI-powered ECG and Holter reporting in real-world healthcare settings. The collaboration pairs Movesense’s medical-grade, single-lead wearable ECG devices with NeuralCloud’s MaxYield and CardioYield software to act as an analysis and reporting layer within an existing health system.
The pilot will run through a third-party healthcare organization and affiliated clinics to validate workflow integration, reporting performance, and operational fit. If successful, it could lay the groundwork for a broader commercial rollout, positioning AIML to scale low-cost, AI-driven cardiac monitoring solutions and potentially expand its footprint in ambulatory and outpatient care without materially increasing clinical workloads.
The most recent analyst rating on (TSE:AIML) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
AI/ML Innovations’ subsidiary Neural Cloud Solutions has hired U.S.-based sales recruiting firm Commission Wolf to build a network of independent representatives for its MaxYield and CardioYield cardiac diagnostics platforms. The effort targets cardiology clinics, OEM partners, diagnostic service providers, and other healthcare organizations as the company advances toward regulatory milestones and U.S. commercialization.
By using 1099 sales contractors with established relationships and regional expertise, Neural Cloud aims to create a scalable, flexible sales infrastructure ready to support early deployments, pilot-to-commercial conversions, and strategic partnerships. The company expects that early investment in sales readiness will shorten the time between regulatory clearance and revenue generation, while ensuring clinically fluent engagement for customers adopting its AI-driven ECG enhancement and reporting technologies.
The most recent analyst rating on (TSE:AIML) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
AI/ML Innovations Inc. has appointed world-renowned cardiologist and research leader Dr. Paul Dorian as Medical Innovation Architect and Head of its Medical Advisory Board, succeeding Peter Kendall as the company advances clinical validation, regulatory engagement, and global deployment of its AI-powered cardiac diagnostic technologies. Dr. Dorian, who has already been advising the company on product strategy and clinical positioning, is expected to play a pivotal role in shaping AIML’s clinical strategy and ensuring its ECG signal-processing platforms meet stringent standards of clinical relevance, safety, and impact, reinforcing the company’s bid to align cutting-edge AI innovation with frontline cardiac care and strengthen its position in regulated clinical markets.
The most recent analyst rating on (TSE:AIML) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
NeuralCloud Solutions, a subsidiary of AI/ML Innovations, has entered a strategic collaboration with Finnish wearable sensor maker Movesense to create bundled ECG monitoring solutions that tightly integrate Movesense’s single-lead wearable devices with NeuralCloud’s AI-driven cardiac platforms. The partnership is designed to deliver cost-efficient, Holter-style cardiac monitoring and reporting across clinical and wellness markets by combining proven, programmable ECG hardware with AI-based signal enhancement, labeling and customizable report generation, strengthening AIML’s go-to-market position and expanding its ability to offer complete device-plus-software cardiac solutions that can accelerate deployment and broaden market reach.
The most recent analyst rating on (TSE:AIML) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
NeuralCloud Solutions, a subsidiary of AI/ML Innovations, has entered a strategic collaboration with Finnish wearable sensor maker Movesense to create bundled ECG monitoring solutions that tightly integrate Movesense’s single-lead wearable ECG hardware with NeuralCloud’s AI-driven cardiac platforms. The partnership is designed to deliver cost-efficient, scalable alternatives to traditional Holter monitoring by combining device-plus-AI offerings for automated ECG analysis, visualization and report generation across clinical, wellness and research settings, strengthening AIML’s go-to-market position and expanding its ability to offer complete, device-enabled cardiac solutions that fit modern digital health workflows.
The most recent analyst rating on (TSE:AIML) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
NeuralCloud Solutions, a subsidiary of AI/ML Innovations Inc., has signed a non-binding commercial term sheet with Lakeshore Cardiology to integrate its CardioYield AI visualization platform, powered by the proprietary MaxYield signal-processing engine, into the clinic’s Holter and ambulatory cardiac monitoring workflows. The staged rollout will begin with internal validation and a limited paid trial at Lakeshore Cardiology, with full systems integration and cloud-based deployment planned once the solution is validated and receives necessary regulatory clearance, positioning AIML to embed its AI-driven ECG analysis more deeply into real-world cardiology practice and potentially raise the standard and efficiency of Holter analysis for clinicians and patients.
The most recent analyst rating on (TSE:AIML) stock is a Sell with a C$0.04 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
AI/ML Innovations Inc. has appointed healthcare and MedTech veteran Erik Suokas as Chief Operating Officer to lead day-to-day operations and drive the commercialization of its AI-driven cardiac platform. The move marks a shift from product development to revenue execution and operational scaling, with Suokas tasked with aligning commercial strategy, contract discipline, delivery readiness, and cross-functional teams to convert growing market interest into repeatable revenue and scalable customer delivery. With more than two decades of experience in regulated healthcare and SaaS environments—and a background spanning clinical, legal, and business training—Suokas is expected to strengthen AIML’s operating backbone, support expansion across clinical, wellness, and enterprise health markets, and enhance the company’s industry positioning as it builds out a more robust commercial and delivery infrastructure.
The most recent analyst rating on (TSE:AIML) stock is a Sell with a C$0.04 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
AI/ML Innovations Inc. has ended its consulting agreement with Campfire Properties Inc., resulting in Peter Kendall’s departure as President and Chief Commercial Officer effective December 29, 2025. CEO and Chairman Paul Duffy will assume the additional role of President, consolidating leadership at the top of the organization and signaling a streamlined executive structure as the company continues to advance its AI-driven digital health platforms.
The most recent analyst rating on (TSE:AIML) stock is a Hold with a C$0.03 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.